EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serenoa Repens (Saw Palmetto) for Lower Urinary Tract Symptoms (LUTS): The Evidence for Efficacy and Safety of Lipidosterolic Extracts. Part III

Stephen B. Strum

Uro · 2021

DOI: 10.3390/uro1030017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Uro, 2021. Verfasst von Stephen B. Strum. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Nutraceuticals, d/b/a Valensa International, Life Extension® Group.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parts I and II of this three-part series indicated how a global review of both English-language and non-English language papers, plus a focus on a lipidosterolic extract of Serenoa repens (LSESr) having a standardized fatty acid profile, have together engendered new insights about the biological activity of LSESr vs. LUTS. In this last part, data from the world literature is presented that confirms that LSESr efficacy is the predominant finding in clinical trials. Despite two placebo-controlled clinical trials performed in the U.S. that failed to confirm a benefit of LSESr vs. placebo in LUTS, the global body of the peer-reviewed literature attests not only to efficacy but also to safety. Results will be presented of important trials that compare LSESr to alpha-blockers such as tamsulosin (Flomax®) as well as to 5α-reductase inhibitors such as finasteride (Proscar®) that demonstrate consistent findings of near equivalency between LSESr and these pharmacologic agents. Studies relating data indicative of an additive effect or synergy between LSESr and tamsulosin will also be presented. The heightened effectiveness of LSESr in men with severe LUTS vs. moderate LUTS expands the importance of our scrutiny of the global literature concerning LSESr. Of great consequence are the contributions of non-English language peer-reviewed publications that have consistently provided evidence of LSESr efficacy in treating LUTS/BPH. These peer-reviewed articles have shown that the effect of LSESr is not that of a placebo. Finally, a comparison of the LSESr extraction products used in the treatment of LUTS, and a discussion of the milieu factors that affect the natural history of LUTS and influence the outcome of clinical trials, complete this detailed analysis of LSESr vs. LUTS.

Förderung

  • U.S. Nutraceuticals, d/b/a Valensa International
  • Life Extension® Group

Zitieren

APA

Strum, S. B. (2021). Serenoa Repens (Saw Palmetto) for Lower Urinary Tract Symptoms (LUTS): The Evidence for Efficacy and Safety of Lipidosterolic Extracts. Part III. Uro. https://doi.org/10.3390/uro1030017

Vancouver

Strum SB. Serenoa Repens (Saw Palmetto) for Lower Urinary Tract Symptoms (LUTS): The Evidence for Efficacy and Safety of Lipidosterolic Extracts. Part III. Uro. 2021. doi:10.3390/uro1030017

BibTeX
@article{Strum2021,
  author = {Strum, Stephen B.},
  title = {Serenoa Repens (Saw Palmetto) for Lower Urinary Tract Symptoms (LUTS): The Evidence for Efficacy and Safety of Lipidosterolic Extracts. Part III},
  journal = {Uro},
  year = {2021},
  doi = {10.3390/uro1030017}
}
Kostenlos starten →